dr. jason luke describes results from the phase iii combi-d trial
Published 10 years ago • 366 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:30
dr. jason luke on sequencing targeted and immunotherapy agents in braf melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
2:08
phase 3 combi-d trial of dabrafenib plus trametinib in metastatic
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
1:26
dr. jason luke discusses the giants of cancer care program
-
1:09
dr. jason luke talks about advances in how melanoma is diagnosed
-
0:59
dr. luke on treatment options in metastatic melanoma
-
45:34
understanding lab results
-
11:49
how immunotherapy is administered - part 1
-
1:15:04
decision making for melanoma, stage iii & beyond
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
8:48
combi-ad: dual-targeted therapy for stage 3 melanoma
-
0:29
key findings from phase i/ii study: fractionated lu-177 psma therapy shows safety and promise
-
1:51
dr. luke on immunotherapy diagnostics in melanoma
-
1:48
dr. luke on current and emerging treatment approaches in metastatic melanoma
-
1:23
dr. jason luke on utilizing the tumor microenvironment as a biomarker for immunotherapy response
-
1:41
dr. luke discusses combination approaches on horizon in melanoma
-
1:20
dr. luke on immunotherapy advancements in melanoma
-
1:10
dr. luke on ongoing studies with immunotherapy in melanoma
-
0:48
dr. michael rotkowitz on the dabrafenib plus trametinib combination for melanoma